Keytruda Combination Gives Celyad’s Off-The-Shelf CAR-T A Shot In The Arm
Allogeneics Still Waiting For Breakthrough
Executive Summary
Celyad has been in the CAR-T field for many years, but hopes that a new focus on allogeneic platforms and new targets will put it ahead of competitors.
You may also be interested in...
BioNTech Looks To AI Partnership To Accelerate Drug Discovery
The German biotech has developed its COVID-19 vaccine in record-breaking time, but artificial intelligence could help accelerate drug discovery over the longer term.
Russia Prepares $10 COVID-19 Vaccine For International Launch
Russia is promising the best of both worlds – a low price with a near-perfect efficacy. While the basic science is plausible, its best-in-class claims are bound to generate skepticism.
A Stroke Of Luck Boosts Oxford/AZ’s “Vaccine For The World”
AstraZeneca's research head admits that the half dose approach was a lucky mistake – but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports